放射治疗结合EGFR靶向抑制剂的原理、现状及在非小细胞肺癌中的应用前景

樊旼 已出版文章查询
樊旼
本平台内已出版文章查询
fanming@fudan.edu.cn
1 蔡旭伟 已出版文章查询
蔡旭伟
本平台内已出版文章查询
1 谢立簃 已出版文章查询
谢立簃
本平台内已出版文章查询
1 傅小龙 已出版文章查询
傅小龙
本平台内已出版文章查询
1 蒋国樑 已出版文章查询
蒋国樑
本平台内已出版文章查询
1

+ 作者地址

1复旦大学附属肿瘤医院放疗科,复旦大学上海医学院肿瘤学系,上海,200032


0
  • 摘要
  • 参考文献
  • 相关文章
  • 统计
放疗增敏作用是提高综合治疗疗效的主要方式.EGFR通路异常激活,酪氨酸激酶(EGFR-TK)活性增强会激活下游信号通路,肿瘤细胞增殖、侵袭、转移和血管生成的生物学特性得到强化,最终促进了肿瘤的发生和进展,且伴有放射抗拒.EGFR靶向抑制剂均具有明确的放射增敏作用,已经在临床中取得了不同程度的成功,并且有望在非小细胞肺癌的治疗中开拓新的领域.

[1] Bentzen SM;Heeren G;Cottier B;Slotman B;Glimelius B;Lievens Y;van den Bogaert W .Towards evidence-based guidelines for radiotherapy infrastructure and staffing needs in Europe: the ESTRO QUARTS project.[J].Radiotherapy and oncology: Journal of the European Society for Therapeutic Radiology and Oncology,2005(3):355-365.

[2] Delaney G;Jacob S;Featherstone C et al.The role of radiotherapy in cancer treatment:estimating optimal utilization from a review of evidence-based clinical guidelines[J].Cancer,2005,104:1129-1137.

[3] Tannock IF .Treatment of cancer with radiation and drugs[J].Journal of Clinical Oncology,1996,14:3156-3174.

[4] Steel GG;Peckham MJ .Exploitable mechanisms in combined radiotherapy-chemotherapy:the concept of additivity[J].Int J Radiat Onc Biol Phys,1979,5:85-91.

[5] Nyati MK;Morgan MA;Feng FY et al.Integration of EGFR inhibitors with radiochemotherapy[J].Nat Ca Rev,2006,6:876-885.

[6] Marks LB .The Pulmonary effects of thoracic irradiation[J].Oncology,1994,8:89-100.

[7] Antonia SJ;Wagner H;Williams C et al.Concurrent paclitaxel/cisplatin with thoracic radiation in patients with stage Ⅲ A/B non-small cell carcinoma of the lung[J].Seminars in Oncology,1995,22:34-37.

[8] Reckzeh B;Merte H;Pfluger KH;Pfab R;Wolf M;Havemann K .Severe lymphocytopenia and interstitial pneumonia in patients treated with paclitaxel and simultaneous radiotherapy for non-small-cell lung cancer.[J].Journal of Clinical Oncology,1996(4):1071-1076.

[9] Hanahan D;Weinberg RA .The hallmarks of cancer[J].Cell,2000,100(01):57-70.

[10] Prenzel N;Fischer OM;Streit S;Hart S;Ullrich A .The epidermal growth factor receptor family as a central element for cellular signal transduction and diversification.[J].Endocrine-related cancer,2001(1):11-31.

[11] Ochs JS .Rationale and clinical basis for combining gefitinib (IRESSA, ZD1839) with radiation therapy for solid tumors.[J].International Journal of Radiation Oncology, Biology, Physics,2004(3):941-949.

[12] Liang K;Ang KK;Milas L;Hunter N;Fan Z .The epidermal growth factor receptor mediates radioresistance.[J].International Journal of Radiation Oncology, Biology, Physics,2003(1):246-254.

[13] Akimoto T;Hunter NR;Buchmiller L et al.Inverse relationship between epidermal growth factor receptor expression and radiocurability of murine carcinomas[J].Clinical Cancer Research,1999,5(10):2884-2890.

[14] Ang KK;Berkey BA;Tu X et al.Impact of epidermal growth factor receptor expression on survival and pattern of relapse in patients with advanced head and neck carcinoma[J].Cancer Research,2002,62(24):7350-7356.

[15] Huang SM;Bock JM;Harari PM .Epidermal growth factor receptor blockade with C225 modulates proliferation,apoptosis,and radiosensitivity in squamous cell carcinomas of the head and neck[J].Cancer Research,1999,59:1935-1940.

[16] Huang SM;Li J;Armstrong EA et al.Modulation of radiation response and tumor-induced angiogenesis after epidermal growth factor receptor inhibition by ZD1839 (Iressa)[J].Cancer Research,2003,62:4300-4306.

[17] Chinnaiyan P;Huang SM;Vallabhaneni G et al.Mechanisms of enhanced radiation response following epidermal growth factor receptor signalinginhibition by Erlotinib (Tarceva)[J].Cancer Research,2005,65:3328-3335.

[18] Tofilon PJ;Saxman S;Coleman CN .Molecular Targets for Radiation Therapy.Bringing Preclinical Data into Clinical Trials[J].Clinical Cancer Research,2003,9:3518-3520.

[19] She Y;Lee F;Chen J;Haimovitz Friedman A;Miller VA;Rusch VR;Kris MG;Sirotnak FM .The epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 selectively potentiates radiation response of human tumors in nude mice, with a marked improvement in therapeutic index.[J].Clinical cancer research,2003(10 pt 1):3773-3778.

[20] Bonner JA;Harari PM;Giralt J;Azarnia N;Shin DM;Cohen RB;Jones CU;Sur R;Raben D;Jassem J;Ove R;Kies MS;Baselga J;Youssoufian H;Amellal N;Rowinsky EK;Ang KK .Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck.[J].The New England journal of medicine,2006(6):567-578.

[21] [OL].http://www.moh.gov.cn/uploadfile/200504/200541512237349.doc,2006-4-22.

[22] 徐宁志,董志伟.中国肿瘤流行状况与防治对策述评[J].肿瘤防治杂志,2003(01):5-8.

[23] Mountain CF .Revisions in the international system for staging lung cancer[J].Chest,1997,111:1710-1717.

[24] Pfister DG;Johnson DH;Azzoli CG et al.American society of clinical oncology treatment of unresectable non-small cell lung cancer guideline:update 2003[J].Journal of Clinical Oncology,2003,22:330-353.

[25] Gandara DR;Chansky K;Albain KS;Leigh BR;Gaspar LE;Lara PN Jr;Burris H;Gumerlock P;Kuebler JP;Bearden JD 3rd;Crowley J;Livingston R .Consolidation docetaxel after concurrent chemoradiotherapy in stage IIIB non-small-cell lung cancer: phase II Southwest Oncology Group Study S9504.[J].Journal of Clinical Oncology,2003(10):2004-2010.

[26] Gaspar L;Scott C;Rotman M et al.Recursive partitioning analysis (RPA) of prognostic factors in three Radiation Therapy Oncology Group (RTOG) brain metastases trials[J].International Journal of Radiation Oncology,Biology,Physics,1997,37(04):745-751.

[27] Ready N;Herndon J;Vokes E.Initial cohort toxicity evaluation for chemoradiotherapy (CRT) and ZD1839 in stage Ⅲ non-small cell lung cancer (NSCLC):A CALGB stratified phase Ⅱ trial(abst)[J].Proceedings of The American Society of Clinical Oncology,2004:7078.

[28] Morris DE;Halle JS;Stinchcombe T.Induction chemotherapy using carboplatin (C),irinotecan (Ⅰ),and paclitaxel (P) with pegfilgrastim support followed by concurrent thoracic conformal radiation therapy (TCRT) with weekly CP and daily gefitinib (Iressa)(abst)[J].Proceedings of The American Society of Clinical Oncology,2005



期刊热词
  • + 更多
  • 字体大小